CPH to expand US footprint after USOTC listing
Finfeed Archived Jun 11, 2021
The US OTC listing gives Creso Pharma Ltd (ASX: CPH) greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.
Bill passed: wide range of psychedelics could be made legal in the US
Finfeed Archived Jun 03, 2021
In what is a major development for Creso Pharma (ASX: CPH), target acquisition company Halucencex Life Sciences is fast tracking its go to market strategy in California. This follows the recent passing of Senate Bill 519 through the California State Senate, which if signed into law, would make a wide range of psychedelic substances including psilocybin legal to use and possess for adults over the age of 21.
CPH further derisks acquisition as Halucenex adds to its psychedelics supply
Finfeed Archived May 14, 2021
Creso Pharma Limited (ASX: CPH, FRA:1X8) target acquisition company Halucenex Life Sciences has nearly doubled its supply of synthetic psilocybin. Halucenex has secured an additional 10 grams of synthetic psilocybin from its manufacturing partner – Canada’s only pharmaceutical grade synthetic psilocybin producer.
Halucenex forms important partnership as psychedelics space heats
Finfeed Archived May 06, 2021
Creso Pharma Limited (ASX: CPH, FRA:1X8) has today announced that its acquisition target Halucenex Life Sciences Inc. has signed an agreement with Nucro-Technics, a Pharmaceutical Contract Research Organization (CRO) that is a partner to pharmaceutical, biologic, and medical device companies located all over the world.
Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing
Finfeed Archived Apr 30, 2021
There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.